CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.47B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
3.47BUSDvs all stocks (USD)
Revenue (TTM)
225.27MUSDvs all stocks (USD)
Profit Margin
-62.17%vs Biotechnology peers
Beta
-0.0910xvs all stocks
52-Week Change
65.11%vs all stocks
Market Capitalization
3.47BUSDvs all stocks (USD)
Enterprise Value
2.51BUSDvs all stocks (USD)
Forward P/E
-9.83xvs Biotechnology peers
Price to Sales (TTM)
15.36xvs Biotechnology peers
Price to Book (MRQ)
3.37xvs Biotechnology peers
Enterprise to Revenue
11.16xvs Biotechnology peers
Enterprise to EBITDA
-13.91xvs Biotechnology peers
Profit Margin
-62.17%vs Biotechnology peers
Operating Margin
-1654.63%vs Biotechnology peers
Return on Assets (TTM)
-10.76%vs Biotechnology peers
Return on Equity (TTM)
-14.28%vs Biotechnology peers
Revenue (TTM)
225.27MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.54USDUpdated Jul 19, 2026Quarterly Revenue Growth
-39.68%vs Biotechnology peers
Gross Profit (TTM)
-114.27MUSDvs all stocks (USD)
EBITDA (TTM)
-180.68MUSDvs all stocks (USD)
Net Income (TTM)
-140.06MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-85.93MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-57.25MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
218.71MUSDFY2025 · Dec 31, 2025Operating Income
-159.31MUSDvs all stocks (USD)
Pre-tax Income
-113.70MUSDFY2025 · Dec 31, 2025Net Income
-113.70MUSDFY2025 · Dec 31, 2025EBIT
-159.31MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-154.72MUSDFY2025 · Dec 31, 2025Research & Development
314.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
63.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
45.62MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-113.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-63.71MUSDFY2025 · Dec 31, 2025Free Cash Flow
-66.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
113.84MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-113.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.59MUSDFY2025 · Dec 31, 2025Stock-based Compensation
46.12MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.70MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.42MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.37MUSDFY2025 · Dec 31, 2025Purchase of Investments
-607.89MUSDFY2025 · Dec 31, 2025Sale of Investments
680.23MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
69.98MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
24.86MUSDFY2025 · Dec 31, 2025Shares Outstanding
87.86MSharesUpdated Jul 19, 2026Float Shares
87.08MSharesUpdated Jul 19, 2026Shares Short
10.33MSharesUpdated Jul 19, 2026Short Ratio
6.53daysvs all stocks
Short % of Shares Outstanding
12.47%vs all stocks
% Held by Insiders
2.23%vs all stocks
% Held by Institutions
101.90%vs all stocks
Total Cash (MRQ)
671.20MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.64USDUpdated Jul 19, 2026Total Debt (MRQ)
28.60MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0305xvs Biotechnology peers
Current Ratio (MRQ)
10.74xvs Biotechnology peers
Book Value per Share (MRQ)
10.67USDUpdated Jul 19, 2026Total Assets
1.11BUSDvs all stocks (USD)
Total Current Assets
666.73MUSDFY2025 · Dec 31, 2025Total Liabilities
86.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
442.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
27.57MUSDFY2025 · Dec 31, 2025Total Current Liabilities
58.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
112.83MUSDFY2025 · Dec 31, 2025Other Short-term Investments
526.56MUSDFY2025 · Dec 31, 2025Accounts Payable
17.58MUSDFY2025 · Dec 31, 2025Short-term Debt
339.00KUSDFY2025 · Dec 31, 2025Long-term Debt
27.57MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-736.54MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.02BUSDvs all stocks (USD)
52-Week Low
21.33USDUpdated Jul 19, 202652-Week High
40.58USDUpdated Jul 19, 202652-Week Change
65.11%vs all stocks
Beta
-0.0910xvs all stocks
50-Day MA
31.87USDUpdated Jul 19, 2026200-Day MA
32.25USDUpdated Jul 19, 2026Avg 10-Day Volume
1.09MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.45MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.57USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 15.36Revenue Growth YoY: -0.40
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.47B, above the global median of $1.15BNotable
Market cap (USD): 3,466,855,456Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Jumpcan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Nhwa Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow